Correlation between inhibitory effect on prolactin secretion and antitumor activity of new ergoline compounds on DMBA-induced tumors in rats
- 1 November 1983
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 19 (11) , 1545-1551
- https://doi.org/10.1016/0277-5379(83)90084-6
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisurideFertility and Sterility, 1982
- Antiprolactinic ergolinesCellular and Molecular Life Sciences, 1980
- Effects of (8β)-8-[(Methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in ratsLife Sciences, 1979
- Prolactin secretion inhibition by a new 8a-amino-ergoline, CH 29-717Cellular and Molecular Life Sciences, 1978
- Mechanisms underlying the prolactin-lowering effect of metergoline in the ratLife Sciences, 1978
- On the Mechanism of Prolactin and Estrogen Action in 7,12 Dimethylbenz(A)anthracene-Induced Mammary Carcimona in the Rat. II.In VivoTumor Responses and Estrogen Receptor1,2,3Endocrinology, 1975
- The response of breast cancer patients with bone pain to L-dopaCancer, 1974
- PROLACTIN DEPENDENCE IN HUMAN BREAST CANCERSThe Lancet, 1972
- Clinical trial of 2-Br-α-ergocryptine (CB154) in advanced breast cancerPublished by Elsevier ,1972
- Growth inhibition of rat mammary carcinoma and endocrine changes produced by 2-Br-α-ergocryptine, a suppressor of lactation and nidationPublished by Elsevier ,1970